Active Substance: Rocuronium bromide.
Overview
Welcome to Dwaey, specifically on ROCALM page.
This medicine contains an important and useful components, as it consists of
Rocuronium bromideis available in the market in concentration
Rocuronium Bromide
Patient w/ biliary tract disease, neuromuscular disease, previous poliomyelitis, burn injury, severe electrolyte disturbances, Eaton-Lambert syndrome, myasthenia gravis, CV disease, resp disease, pulmonary HTN; obese patients. Renal and hepatic impairment. Elderly. Pregnancy and lactation. Monitoring Parameters Monitor heart rate, BP, twitch response, assisted ventilation status. Lactation: not known if excreted in breast milk; effect on nursing infant not known
Endotracheal intubation, Aid controlled ventilation, Muscle relaxant in general anesthesia
Hypersensitivity.
1-10% Transient hypotension (1-2%),Hypertension (1-2%) <1% Dose-related tachycardia,Apnea,Abnormal ECG,Injection site edema,Hiccups,Pruritus,Nausea,Wheezing,Residual muscle weakness,Allergic or idiosyncratic hypersensitivity reactions Potentially Fatal: Abnormal ECG, arrhythmia, bronchospasm, anaphylaxis and malignant hyperthermia.
3
Rocuronium is a competitive neuromuscular blocker that acts by blocking the binding of acetylcholine to receptors on the motor endplate, inhibiting depolarisation.
May cause enhanced block when used with lidocaine, procainamide, quinidine, verapamil, aminoglycosides, inhalational anaesthetics and vancomycin. May cause prolonged paralysis when used with clindamycin. Anticholinesterases such as pyridostigmine and galantamine may antagonise the effect of rocuronium. Chronic use of carbamazepine or phenytoin may lead to resistance to rocuronium.
Information not available